Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
21.83-0.34 (-1.53%)
At close: 04:00PM EDT
21.83 0.00 (0.00%)
After hours: 06:06PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.44B
Enterprise value 3.07B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.81
Enterprise value/revenue N/A
Enterprise value/EBITDA -7.66

Trading information

Stock price history

Beta (5Y monthly) 1.43
52-week change 3-24.88%
S&P500 52-week change 316.57%
52-week high 335.98
52-week low 319.85
50-day moving average 323.65
200-day moving average 328.42

Share statistics

Avg vol (3-month) 3688.08k
Avg vol (10-day) 3813.59k
Shares outstanding 5157.49M
Implied shares outstanding 6157.49M
Float 859.61M
% held by insiders 117.51%
% held by institutions 188.78%
Shares short (14 Sept 2023) 46.02M
Short ratio (14 Sept 2023) 410.39
Short % of float (14 Sept 2023) 413.47%
Short % of shares outstanding (14 Sept 2023) 43.82%
Shares short (prior month 14 Aug 2023) 45.08M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 June 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-33.43%
Return on equity (ttm)-98.73%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -393.47M
Net income avi to common (ttm)-396.57M
Diluted EPS (ttm)-2.51
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)736.43M
Total cash per share (mrq)4.68
Total debt (mrq)481.44M
Total debt/equity (mrq)137.36%
Current ratio (mrq)11.47
Book value per share (mrq)2.23

Cash flow statement

Operating cash flow (ttm)-340.13M
Levered free cash flow (ttm)-203.52M